Shang Li
Jiangsu Key Laboratory Of Bioactive Natural Product Research And State Key Laboratory Of Natural Medicines
Nanjing, 210009, China
Nanjing, 210009, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 27 publications
Correction to "Discovery of Dual CDK6/BRD4 Inhibitor Inducing Apoptosis and Increasing the Sensitivity of Ferroptosis in Triple-Negative Breast Cancer".
Journal: Journal of medicinal chemistry
Published: January 28, 2025
Discovery of Dual CDK6/BRD4 Inhibitor Inducing Apoptosis and Increasing the Sensitivity of Ferroptosis in Triple-Negative Breast Cancer.
Journal: Journal of medicinal chemistry
Published: November 22, 2024
Polypharmacological Drug Design Guided by Integrating Phenotypic and Restricted Fragment Docking Strategies.
Journal: Journal of medicinal chemistry
Published: September 19, 2024
Discovery of Covalent MLKL PROTAC Degraders via Optimization of a Theophylline Derivative Ligand for Treating Necroptosis.
Journal: Journal of medicinal chemistry
Published: August 24, 2024
Improving tumor sensitivity by the introduction of an ester chain to triaryl derivatives targeting PD-1/PD-L1.
Journal: European journal of medicinal chemistry
Published: March 26, 2024
Dual target PARP1/EZH2 inhibitors inducing excessive autophagy and producing synthetic lethality for triple-negative breast cancer therapy.
Journal: European journal of medicinal chemistry
Published: October 05, 2023
Indirubin derivatives as bifunctional molecules inducing DNA damage and targeting PARP for the treatment of cancer.
Journal: European journal of medicinal chemistry
Published: July 13, 2023
Design, synthesis and mechanism studies of dual EZH2/BRD4 inhibitors for cancer therapy.
Journal: Bioorganic & medicinal chemistry
Published: April 27, 2023
Design and synthesis of antiviral pseudo-natural products through effective one-step acylmethylation macrocyclization.
Journal: Chinese journal of natural medicines
Published: March 12, 2023
Oxazole-4-carboxamide/butylated hydroxytoluene hybrids with GSK-3β inhibitory and neuroprotective activities against Alzheimer's disease.
Journal: European journal of medicinal chemistry
Published: February 24, 2023
Discovery of Sibiriline derivatives as novel receptor-interacting protein kinase 1 inhibitors.
Journal: European journal of medicinal chemistry
Published: December 20, 2022
Last Updated: 09/26/2026